![]() |
Name |
Pestalopyrone
|
Molecular Formula | C10H12O3 | |
IUPAC Name* |
6-[(E)-but-2-en-2-yl]-4-methoxypyran-2-one
|
|
SMILES |
C/C=C(\C)/C1=CC(=CC(=O)O1)OC
|
|
InChI |
InChI=1S/C10H12O3/c1-4-7(2)9-5-8(12-3)6-10(11)13-9/h4-6H,1-3H3/b7-4+
|
|
InChIKey |
HOXZLCMLRLXRIN-QPJJXVBHSA-N
|
|
Synonyms |
pestalopyrone; CHEMBL454237; BS-1284; 6-[(E)-but-2-en-2-yl]-4-methoxypyran-2-one
|
|
CAS | NA | |
PubChem CID | 14841097 | |
ChEMBL ID | CHEMBL454237 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 180.2 | ALogp: | 2.1 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 35.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 13 | QED Weighted: | 0.702 |
Caco-2 Permeability: | -4.602 | MDCK Permeability: | 0.00001740 |
Pgp-inhibitor: | 0.08 | Pgp-substrate: | 0.016 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.032 |
30% Bioavailability (F30%): | 0.99 |
Blood-Brain-Barrier Penetration (BBB): | 0.071 | Plasma Protein Binding (PPB): | 89.65% |
Volume Distribution (VD): | 1.349 | Fu: | 22.98% |
CYP1A2-inhibitor: | 0.95 | CYP1A2-substrate: | 0.954 |
CYP2C19-inhibitor: | 0.716 | CYP2C19-substrate: | 0.618 |
CYP2C9-inhibitor: | 0.178 | CYP2C9-substrate: | 0.814 |
CYP2D6-inhibitor: | 0.123 | CYP2D6-substrate: | 0.879 |
CYP3A4-inhibitor: | 0.062 | CYP3A4-substrate: | 0.309 |
Clearance (CL): | 8.857 | Half-life (T1/2): | 0.741 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.189 |
Drug-inuced Liver Injury (DILI): | 0.334 | AMES Toxicity: | 0.017 |
Rat Oral Acute Toxicity: | 0.088 | Maximum Recommended Daily Dose: | 0.189 |
Skin Sensitization: | 0.214 | Carcinogencity: | 0.478 |
Eye Corrosion: | 0.923 | Eye Irritation: | 0.985 |
Respiratory Toxicity: | 0.461 |